Please assess the completion status of the following clinical trial:

Trial Title: The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patient must have at least one inpatient, one physician office visit, or one emergency room visit with a diagnosis of AF on the index date or during the pre-index period.~* Patients must be continuously enrolled in a health plan during the pre-index period~* Patient must have a prescription for dabigatran or warfarin~* Patient must be treatment naive from all oral anticoagulant (OAC) use prior to first OAC prescription~* Aged 18-89 years on the index date. The index date is defined as the date of the first OAC prescription~Exclusion criteria:~* Diagnosis of hyperthyroidism during the pre-index period,~* Having claims for any of the following within 3 months prior to the first diagnosis of AF: cardiac surgery, pericarditis, myocarditis, pulmonary embolism.~* Any patients with at least one medical claim for valvular heart disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- dabigatran (Type: None): None
- warfarin (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).